Alphabet agreed to buy Intersect Power for $4.75 billion to secure clean energy and speed new data center buildouts, while some Texas and California assets remain independent.

Northwestern researchers report NU‑9 lowered a newly discovered toxic amyloid‑beta oligomer and blunted early brain inflammation in mice, pointing to a possible pre‑symptomatic intervention.

Tech giants warn employees on visas about international travel risks due to long delays in visa stamping appointments, as American embassies prioritize security vetting.

UT Southwestern researchers found SIGLEC12 drives membrane rupture during necroptosis, revealing a potential drug target for sepsis, inflammatory and neurodegenerative diseases.

A UH Mānoa team won a top ASRU hackathon prize for Aurion, an AI co‑pilot that flags hidden distress in speech and trims CHW paperwork. The project hopes to free time for frontline care.

StartUpNV‑affiliated funds have mobilized hundreds of local investors and returned cash faster than many coastal VCs, reshaping Nevada’s startup playbook. Early results show quicker payouts and growing local participation.

Sonoma couple Linda Shore and David Barker have spent years teaching hands-on science in Tibetan monasteries and building traveling exhibits that translate Western science into monastic classrooms.

Aaron Greenspan says a San Francisco judge’s Nov. 13 order included AI‑generated citation errors. His motion asks the court to correct the record and revive parts of his Musk suit.

Governor Hochul signed the RAISE Act in New York to regulate AI development with safety and transparency, establishing oversight and imposing penalties for non-compliance.

Cuyahoga County's Residential Solar Co-op program celebrates its 500th solar panel installation, highlighting community adoption of clean energy and expected energy cost savings.

At an xAI all‑hands in San Francisco, Elon Musk told staff the next two to three years are make-or-break as he pushes massive compute and funding plans.

BioMarin will buy Amicus for roughly $4.8 billion, folding two marketed rare‑disease drugs into its portfolio as the companies eye a Q2 2026 close. The agreement is subject to shareholder and regulatory approvals.

A UC San Diego‑led team won Curebound’s $1M Cure Prize to build a multi‑modal AI that could find pancreatic cancer earlier. The award is meant to push promising algorithms toward clinical use.